Albireo Pharma Inc.
https://www.albireopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Albireo Pharma Inc.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.
CymaBay Appears Stronger Threat To Ocaliva In PBC Than Ipsen/Genfit
CymaBay and Genfit have been positioning their failed NASH candidates, both PPAR agonists, for approval in second-line primary biliary cholangitis. Analysts call both approvable, but say CymaBay’s drug has a better overall profile.
Ipsen Buoyant Despite EMA’s Bylvay Orphan Status Block
The French company plans to refile Bylvay for Alagille syndrome under a new brand name after the EMA's Committee for Orphan Medicinal Products said the drug did not meet its 'significant benefit' criteria.
Ipsen's Desire For Dealmaking Burns Bright
CEO David Loew tells Scrip that valuations to do deals with biotechs “are now at a reasonable level [and] we are screening companies very actively as we speak."
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Albireo AB
- Biodel Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice